Kenvue Inc. (NYSE:KVUE - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 59,242 call options on the company. This is an increase of approximately 290% compared to the average daily volume of 15,181 call options.
Analysts Set New Price Targets
KVUE has been the subject of several analyst reports. Barclays raised their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Evercore ISI began coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Redburn Atlantic began coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price for the company. Finally, Canaccord Genuity Group lifted their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and an average price target of $25.33.
Get Our Latest Report on KVUE
Kenvue Stock Performance
Shares of Kenvue stock traded down $0.03 on Thursday, hitting $21.65. 16,854,133 shares of the company's stock were exchanged, compared to its average volume of 16,434,733. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a 1 year low of $17.67 and a 1 year high of $25.17. The company has a 50-day simple moving average of $23.21 and a 200-day simple moving average of $22.62. The stock has a market capitalization of $41.53 billion, a PE ratio of 40.84, a PEG ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter in the previous year, the company earned $0.28 EPS. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. As a group, equities analysts anticipate that Kenvue will post 1.14 EPS for the current year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.79%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 149.09%.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue during the 1st quarter valued at $30,000. SRS Capital Advisors Inc. lifted its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. TruNorth Capital Management LLC purchased a new stake in Kenvue in the 1st quarter worth $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the 1st quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after buying an additional 1,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
